Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market? Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira’s patent expiry. Previous Article The Fed WANTS a Bear Market & Recession Next Article Want Your Employees Back in the Office? Here's How to Make It a Place They Want to Be.
